{"name":"Santen Inc.","slug":"santen-inc","ticker":"","exchange":"","domain":"santen.com","description":"Santen Inc. is a leading ophthalmic pharmaceutical company dedicated to improving the lives of patients with eye diseases and conditions. The company has a robust pipeline with several drugs in Phase 3 trials, focusing on innovative treatments for ocular disorders.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1996-01-01","label":"Levaquin first approved","drug":"Levaquin","drugSlug":"levofloxacin-in-dextrose-5-in-plastic-container","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"neuroscience","drugs":[{"name":"1.5% levofloxacin ophthalmic solution","genericName":"1.5% levofloxacin ophthalmic solution","slug":"1-5-levofloxacin-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"DE-104 high concentration","genericName":"DE-104 high concentration","slug":"de-104-high-concentration","indication":"Other","status":"phase_1"},{"name":"DE-112","genericName":"DE-112","slug":"de-112","indication":"Other","status":"phase_1"},{"name":"DE-120","genericName":"DE-120","slug":"de-120","indication":"Other","status":"phase_2"},{"name":"DE-127 Ophthalmic Solution low dose","genericName":"DE-127 Ophthalmic Solution low dose","slug":"de-127-ophthalmic-solution-low-dose","indication":"Other","status":"phase_2"},{"name":"0.0015% tafluprost","genericName":"0.0015% tafluprost","slug":"0-0015-tafluprost","indication":"Other","status":"marketed"},{"name":"0.005% Latanoprost Ophthalmic Solution","genericName":"0.005% Latanoprost Ophthalmic Solution","slug":"0-005-latanoprost-ophthalmic-solution","indication":"Other","status":"marketed"},{"name":"Cyclosporine NOVA22007 0.05%","genericName":"Cyclosporine NOVA22007 0.05%","slug":"cyclosporine-nova22007-0-05","indication":"Treatment of uveitis","status":"phase_2"},{"name":"DE-105 ophthalmic solution","genericName":"DE-105 ophthalmic solution","slug":"de-105-ophthalmic-solution","indication":"Other","status":"phase_2"},{"name":"DE-110 ophthalmic suspension low dose","genericName":"DE-110 ophthalmic suspension low dose","slug":"de-110-ophthalmic-suspension-low-dose","indication":"Other","status":"phase_2"},{"name":"DE-117 High Dose ophthalmic solution","genericName":"DE-117 High Dose ophthalmic solution","slug":"de-117-high-dose-ophthalmic-solution","indication":"Other","status":"phase_2"},{"name":"DE-117 Low Dose ophthalmic solution","genericName":"DE-117 Low Dose ophthalmic solution","slug":"de-117-low-dose-ophthalmic-solution","indication":"Other","status":"phase_2"},{"name":"DE-117 Ophthalmic Solution QD","genericName":"DE-117 Ophthalmic Solution QD","slug":"de-117-ophthalmic-solution-qd","indication":"Other","status":"phase_2"},{"name":"DE-126 Ophthalmic Solution 0.002% QD","genericName":"DE-126 Ophthalmic Solution 0.002% QD","slug":"de-126-ophthalmic-solution-0-002-qd","indication":"Other","status":"phase_2"},{"name":"DE-127 Ophthalmic Solution high dose","genericName":"DE-127 Ophthalmic Solution high dose","slug":"de-127-ophthalmic-solution-high-dose","indication":"Other","status":"phase_2"},{"name":"NOVA63035 \"Corticosteroid\"","genericName":"NOVA63035 \"Corticosteroid\"","slug":"nova63035-corticosteroid","indication":"Inflammatory ocular conditions (likely, based on Santen's focus)","status":"marketed"},{"name":"STN1010904 ophthalmic suspension 0.1% BID","genericName":"STN1010904 ophthalmic suspension 0.1% BID","slug":"stn1010904-ophthalmic-suspension-0-1-bid","indication":"Other","status":"phase_2"},{"name":"Tafluprost, timolol maleate","genericName":"Tafluprost, timolol maleate","slug":"tafluprost-timolol-maleate","indication":"Other","status":"phase_2"},{"name":"Up4U","genericName":"DIQUAFOSOL","slug":"diquafosol","indication":"Tear film insufficiency","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"immunology","drugs":[{"name":"DE-117B Eye Drops","genericName":"DE-117B Eye Drops","slug":"de-117b-eye-drops","indication":"Glaucoma or ocular hypertension","status":"phase_3"},{"name":"DE-108","genericName":"DE-108","slug":"de-108","indication":"Glaucoma and ocular hypertension","status":"phase_3"},{"name":"DE-114 ophthalmic solution","genericName":"DE-114 ophthalmic solution","slug":"de-114-ophthalmic-solution","indication":"Glaucoma or ocular hypertension","status":"phase_3"},{"name":"Tafluprost ophthalmic solution 0.0015%","genericName":"Tafluprost ophthalmic solution 0.0015%","slug":"tafluprost-ophthalmic-solution-0-0015","indication":"Glaucoma, ocular hypertension","status":"phase_3"},{"name":"DE-111 ophthalmic solution","genericName":"DE-111 ophthalmic solution","slug":"de-111-ophthalmic-solution","indication":"Glaucoma or ocular hypertension","status":"phase_3"},{"name":"DE-117","genericName":"DE-117","slug":"de-117","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"DE-117 Middle Dose ophthalmic solution","genericName":"DE-117 Middle Dose ophthalmic solution","slug":"de-117-middle-dose-ophthalmic-solution","indication":"Glaucoma or ocular hypertension (Phase 2)","status":"phase_2"},{"name":"DE-117 Ophthalmic Solution","genericName":"DE-117 Ophthalmic Solution","slug":"de-117-ophthalmic-solution","indication":"Glaucoma and ocular hypertension","status":"phase_3"},{"name":"DE-130A","genericName":"DE-130A","slug":"de-130a","indication":"Glaucoma or ocular hypertension (Phase 3 indication)","status":"phase_3"},{"name":"DE-130A/DE-130A","genericName":"DE-130A/DE-130A","slug":"de-130a-de-130a","indication":"Glaucoma","status":"phase_3"},{"name":"Eybelis ophthalmic solution 0.002%","genericName":"Eybelis ophthalmic solution 0.002%","slug":"eybelis-ophthalmic-solution-0-002","indication":"Open-angle glaucoma","status":"marketed"},{"name":"Xalatan®/DE-130A","genericName":"Xalatan®/DE-130A","slug":"xalatan-de-130a","indication":"Glaucoma","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"Levaquin","genericName":"Levofloxacin","slug":"levofloxacin-in-dextrose-5-in-plastic-container","indication":"Acute Moraxella catarrhalis bronchitis","status":"marketed"},{"name":"STN1013800 ophthalmic solution","genericName":"STN1013800 ophthalmic solution","slug":"stn1013800-ophthalmic-solution","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_3"},{"name":"DE-089 ophthalmic solution","genericName":"DE-089 ophthalmic solution","slug":"de-089-ophthalmic-solution","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"DE-101 ophthalmic suspension","genericName":"DE-101 ophthalmic suspension","slug":"de-101-ophthalmic-suspension","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"DE-104 ophthalmic solution","genericName":"DE-104 ophthalmic solution","slug":"de-104-ophthalmic-solution","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"DE-117 Ophthalmic Solution BID","genericName":"DE-117 Ophthalmic Solution BID","slug":"de-117-ophthalmic-solution-bid","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"DE-117 ophthalmic solution high","genericName":"DE-117 ophthalmic solution high","slug":"de-117-ophthalmic-solution-high","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"},{"name":"STN1012600 ophthalmic solution 0.002%","genericName":"STN1012600 ophthalmic solution 0.002%","slug":"stn1012600-ophthalmic-solution-0-002","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"NOVA22007","genericName":"NOVA22007","slug":"nova22007","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Masked Ikervis","genericName":"Masked Ikervis","slug":"masked-ikervis","indication":"Dry eye disease with significant inflammatory component","status":"phase_3"},{"name":"NOVA22007 (Ciclosporin 0.1%)","genericName":"NOVA22007 (Ciclosporin 0.1%)","slug":"nova22007-ciclosporin-0-1","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Open-label Ikervis","genericName":"Open-label Ikervis","slug":"open-label-ikervis","indication":"Severe keratoconjunctivitis sicca (dry eye disease) in adults","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Lucentis","genericName":"Lucentis","slug":"lucentis","indication":"Age related macular degeneration","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"NOVA22007 ''Ciclosporin''","genericName":"NOVA22007 ''Ciclosporin''","slug":"nova22007-ciclosporin","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"}]}],"pipeline":[{"name":"Levaquin","genericName":"Levofloxacin","slug":"levofloxacin-in-dextrose-5-in-plastic-container","phase":"marketed","mechanism":"Levaquin works by inhibiting bacterial DNA replication and transcription by binding to the enzyme DNA gyrase.","indications":["Acute Moraxella catarrhalis bronchitis","Acute bacterial bronchitis","Acute bacterial sinusitis","Acute exacerbation of chronic bronchitis","Acute maxillary sinusitis"],"catalyst":""},{"name":"DE-117B Eye Drops","genericName":"DE-117B Eye Drops","slug":"de-117b-eye-drops","phase":"phase_3","mechanism":"DE-117B is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.","indications":["Glaucoma or ocular hypertension"],"catalyst":""},{"name":"Lucentis","genericName":"Lucentis","slug":"lucentis","phase":"marketed","mechanism":"Vascular endothelial growth factor A","indications":["Age related macular degeneration","Branch retinal vein occlusion with macular edema","Central retinal vein occlusion with macular edema","Choroidal retinal neovascularization","Diabetic retinopathy"],"catalyst":""},{"name":"1.5% levofloxacin ophthalmic solution","genericName":"1.5% levofloxacin ophthalmic solution","slug":"1-5-levofloxacin-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-104 high concentration","genericName":"DE-104 high concentration","slug":"de-104-high-concentration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-108","genericName":"DE-108","slug":"de-108","phase":"phase_3","mechanism":"DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance.","indications":["Glaucoma and ocular hypertension"],"catalyst":""},{"name":"DE-112","genericName":"DE-112","slug":"de-112","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-114 ophthalmic solution","genericName":"DE-114 ophthalmic solution","slug":"de-114-ophthalmic-solution","phase":"phase_3","mechanism":"DE-114 is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","indications":["Glaucoma or ocular hypertension"],"catalyst":""},{"name":"DE-120","genericName":"DE-120","slug":"de-120","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-127 Ophthalmic Solution low dose","genericName":"DE-127 Ophthalmic Solution low dose","slug":"de-127-ophthalmic-solution-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NOVA22007","genericName":"NOVA22007","slug":"nova22007","phase":"phase_3","mechanism":"NOVA22007 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces neurogenic inflammation and pain signaling in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Ocular pain and inflammation"],"catalyst":""},{"name":"STN1013800 ophthalmic solution","genericName":"STN1013800 ophthalmic solution","slug":"stn1013800-ophthalmic-solution","phase":"phase_3","mechanism":"STN1013800 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"Tafluprost ophthalmic solution 0.0015%","genericName":"Tafluprost ophthalmic solution 0.0015%","slug":"tafluprost-ophthalmic-solution-0-0015","phase":"phase_3","mechanism":"Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.","indications":["Glaucoma, ocular hypertension"],"catalyst":""},{"name":"0.0015% tafluprost","genericName":"0.0015% tafluprost","slug":"0-0015-tafluprost","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"0.005% Latanoprost Ophthalmic Solution","genericName":"0.005% Latanoprost Ophthalmic Solution","slug":"0-005-latanoprost-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cyclosporine NOVA22007 0.05%","genericName":"Cyclosporine NOVA22007 0.05%","slug":"cyclosporine-nova22007-0-05","phase":"phase_2","mechanism":"Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.","indications":["Treatment of uveitis"],"catalyst":""},{"name":"DE-089 ophthalmic solution","genericName":"DE-089 ophthalmic solution","slug":"de-089-ophthalmic-solution","phase":"phase_2","mechanism":"DE-089 ophthalmic solution is a corticosteroid used to treat inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye","Treatment of non-infectious keratitis and anterior uveitis"],"catalyst":""},{"name":"DE-101 ophthalmic suspension","genericName":"DE-101 ophthalmic suspension","slug":"de-101-ophthalmic-suspension","phase":"phase_2","mechanism":"DE-101 ophthalmic suspension is an anti-inflammatory agent that reduces inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"DE-104 ophthalmic solution","genericName":"DE-104 ophthalmic solution","slug":"de-104-ophthalmic-solution","phase":"phase_2","mechanism":"DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"DE-105 ophthalmic solution","genericName":"DE-105 ophthalmic solution","slug":"de-105-ophthalmic-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-110 ophthalmic suspension low dose","genericName":"DE-110 ophthalmic suspension low dose","slug":"de-110-ophthalmic-suspension-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-111 ophthalmic solution","genericName":"DE-111 ophthalmic solution","slug":"de-111-ophthalmic-solution","phase":"phase_3","mechanism":"DE-111 is a selective dopamine D1 receptor agonist that enhances aqueous humor outflow to reduce intraocular pressure in glaucoma.","indications":["Glaucoma or ocular hypertension"],"catalyst":""},{"name":"DE-117","genericName":"DE-117","slug":"de-117","phase":"phase_3","mechanism":"DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"DE-117 High Dose ophthalmic solution","genericName":"DE-117 High Dose ophthalmic solution","slug":"de-117-high-dose-ophthalmic-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-117 Low Dose ophthalmic solution","genericName":"DE-117 Low Dose ophthalmic solution","slug":"de-117-low-dose-ophthalmic-solution","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-117 Middle Dose ophthalmic solution","genericName":"DE-117 Middle Dose ophthalmic solution","slug":"de-117-middle-dose-ophthalmic-solution","phase":"phase_2","mechanism":"DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by improving aqueous humor outflow through the trabecular meshwork and Schlemm's canal.","indications":["Glaucoma or ocular hypertension (Phase 2)"],"catalyst":""},{"name":"DE-117 Ophthalmic Solution","genericName":"DE-117 Ophthalmic Solution","slug":"de-117-ophthalmic-solution","phase":"phase_3","mechanism":"DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","indications":["Glaucoma and ocular hypertension"],"catalyst":""},{"name":"DE-117 Ophthalmic Solution BID","genericName":"DE-117 Ophthalmic Solution BID","slug":"de-117-ophthalmic-solution-bid","phase":"phase_2","mechanism":"DE-117 Ophthalmic Solution BID is an anti-inflammatory agent.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"DE-117 Ophthalmic Solution QD","genericName":"DE-117 Ophthalmic Solution QD","slug":"de-117-ophthalmic-solution-qd","phase":"phase_2","mechanism":"DE-117 is a selective EP2 receptor agonist that lowers intraocular pressure through increased uveoscleral outflow.","indications":[],"catalyst":""},{"name":"DE-117 ophthalmic solution high","genericName":"DE-117 ophthalmic solution high","slug":"de-117-ophthalmic-solution-high","phase":"phase_2","mechanism":"DE-117 ophthalmic solution high is an anti-inflammatory agent.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"DE-126 Ophthalmic Solution 0.002% QD","genericName":"DE-126 Ophthalmic Solution 0.002% QD","slug":"de-126-ophthalmic-solution-0-002-qd","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-127 Ophthalmic Solution high dose","genericName":"DE-127 Ophthalmic Solution high dose","slug":"de-127-ophthalmic-solution-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DE-130A","genericName":"DE-130A","slug":"de-130a","phase":"phase_3","mechanism":"DE-130A is a small-molecule inhibitor designed to modulate intraocular pressure and inflammation in the eye.","indications":["Glaucoma or ocular hypertension (Phase 3 indication)"],"catalyst":""},{"name":"DE-130A/DE-130A","genericName":"DE-130A/DE-130A","slug":"de-130a-de-130a","phase":"phase_3","mechanism":"DE-130A is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma and ocular hypertension.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Eybelis ophthalmic solution 0.002%","genericName":"Eybelis ophthalmic solution 0.002%","slug":"eybelis-ophthalmic-solution-0-002","phase":"marketed","mechanism":"Eybelis is a selective rho kinase inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Masked Ikervis","genericName":"Masked Ikervis","slug":"masked-ikervis","phase":"phase_3","mechanism":"Ikervis is a cyclosporine A ophthalmic emulsion that suppresses local immune-mediated inflammation in the ocular surface.","indications":["Dry eye disease with significant inflammatory component"],"catalyst":""},{"name":"NOVA22007 ''Ciclosporin''","genericName":"NOVA22007 ''Ciclosporin''","slug":"nova22007-ciclosporin","phase":"phase_3","mechanism":"Ciclosporin suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing inflammatory immune responses.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Uveitis","Other immune-mediated ocular inflammatory conditions"],"catalyst":""},{"name":"NOVA22007 (Ciclosporin 0.1%)","genericName":"NOVA22007 (Ciclosporin 0.1%)","slug":"nova22007-ciclosporin-0-1","phase":"phase_3","mechanism":"Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"NOVA63035 \"Corticosteroid\"","genericName":"NOVA63035 \"Corticosteroid\"","slug":"nova63035-corticosteroid","phase":"marketed","mechanism":"NOVA63035 is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.","indications":["Inflammatory ocular conditions (likely, based on Santen's focus)"],"catalyst":""},{"name":"Open-label Ikervis","genericName":"Open-label Ikervis","slug":"open-label-ikervis","phase":"phase_3","mechanism":"Ikervis is a lipid emulsion eye drop that reduces inflammation and promotes tear production in dry eye disease by delivering cyclosporine to the ocular surface.","indications":["Severe keratoconjunctivitis sicca (dry eye disease) in adults"],"catalyst":""},{"name":"STN1010904 ophthalmic suspension 0.1% BID","genericName":"STN1010904 ophthalmic suspension 0.1% BID","slug":"stn1010904-ophthalmic-suspension-0-1-bid","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"STN1012600 ophthalmic solution 0.002%","genericName":"STN1012600 ophthalmic solution 0.002%","slug":"stn1012600-ophthalmic-solution-0-002","phase":"phase_3","mechanism":"STN1012600 ophthalmic solution 0.002% is a corticosteroid used to reduce inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"Tafluprost, timolol maleate","genericName":"Tafluprost, timolol maleate","slug":"tafluprost-timolol-maleate","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Up4U","genericName":"DIQUAFOSOL","slug":"diquafosol","phase":"marketed","mechanism":"P2Y purinoceptor 2","indications":["Tear film insufficiency"],"catalyst":""},{"name":"Xalatan®/DE-130A","genericName":"Xalatan®/DE-130A","slug":"xalatan-de-130a","phase":"phase_3","mechanism":"Xalatan is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOdEZjdzFFSXpHb0lId0VTYTU4ZzFVNzA5M3BOUGpxVUQwWUxOMlhlMGFqc3NuQUpOVWdSbnNvcF8za1dmT1B5eVV5aUhMNzRRS18wUlNWQjFUU1FwdFNKdkRFV0JQZVZwQU5ySjJMUDFWQXRnajNIeHNKcFU1ZnQ2UkV3UXdNRmZsQTVZQTVGbTVaOG9GbThsX0Z3eENKZkJwcnZTMTQzcWhyV1RkQ3RmQlpuaG1wOGo4dVkxTHZOUHlYc0QyNHZz?oc=5","date":"2026-04-07","type":"pipeline","source":"AD HOC NEWS","summary":"Santen Pharmaceutical stock: What you should know now before investing - AD HOC NEWS","headline":"Santen Pharmaceutical stock: What you should know now before investing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQNHRuelV3alNMY3l3Y2tNYlMzVUJmbndxLURqRE9YVk80TXNkXzZ3VzctUUU3RzM1QjhtWGJNRHFZenhVOVJac0FidDYtT3pjTTNzSFlTQ3QtUWxyazNDWEoyOU5WenRvekQwM1RuV3ZKS3BYekdWQnRqNURxTE0wQk5KQUNaM1NoZ2YzZmg1eG9rZGJmWWFESXhHYmRoZmc2UDNrYTZwOWhHcDAydHdiYmJtYVQ1aXY0azVCZW5kM2tBZ0JQbDA2bVJhSjJZS1Jpak5OSw?oc=5","date":"2026-04-02","type":"deal","source":"MarketBeat","summary":"Santen Pharmaceutical (OTCMKTS:SNPHY) Sees Unusually-High Trading Volume - Should You Buy? - MarketBeat","headline":"Santen Pharmaceutical (OTCMKTS:SNPHY) Sees Unusually-High Trading Volume - Should You Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZm9ERG9xbHlCWGV2VUNXNDkxc3dDR0ZadUtrNkRsUndVT0ZVcUJOemRWVWNFMUVBNXdFMUZwWmIwVndQamR1QjQyU20zbDF1UmlMQUozd2R1eXN1c1JvWjZucmRuUDIzcWFVOUgtYU9fQjNTSC1zaW5iVUV4UjJ6a2VRMnJJc20yVGpLVUpmNWgxMzBHaXByUmYxUEF5SkY5UUstSDQ3Vzg?oc=5","date":"2026-03-28","type":"pipeline","source":"Yahoo Finance","summary":"Assessing Santen Pharmaceutical (TSE:4536) Valuation After Recent Share Price Strength - Yahoo Finance","headline":"Assessing Santen Pharmaceutical (TSE:4536) Valuation After Recent Share Price Strength","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Why You Might Be Interested In Santen Pharmaceutical Co., Ltd. (TSE:4536) For Its Upcoming Dividend - simplywall.st","headline":"Why You Might Be Interested In Santen Pharmaceutical Co., Ltd. (TSE:4536) For Its Upcoming Dividend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZjdGdjg2VUI5UVRfb0xfa3hmamhYVnlYV0o0UUUwQlk5OUZCbGV6SlhFZWgzeWhReEdNWVI2X0lkQ2Z5eWdlNjlSMkZHLVJHVVN2VEktWTJZLVNCeEo0c0Fadnl3d0tVVGFHV3ZIaWE0cy14V2ZDSkVaSHhtN1E3cnZFM1RRWFhEY2UyU0RfWGdKelBi?oc=5","date":"2026-01-08","type":"regulatory","source":"Yahoo Finance","summary":"RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% - Yahoo Finance","headline":"RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic S","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQU2pJb3dyaklsUjdfcUdUUHNBcWVUQmtOdmpYdTVwVjk3U0habUdtTl9GV2ttWTI2OWVQTGRNaFZncC1xcHFJSVp6bUhELTZjZ190OUxmRkRMMmtTRTVxbV9IWFhfX192ZXFrSl8xWUd2MFVJRXlmSkJRbUxYd1R0Q3FiRV9GdHB0OVFIS3FKS2FKeFdYaVlGN0RFcjdXYk41SlF1OVZVT0YzSmZaT19QNW1zT3NvTzdDMGFSSVBacG00a2Vrejc3dVFxVzRpSjJheTR2cVJTMzU?oc=5","date":"2025-12-06","type":"pipeline","source":"BioSpectrum Asia","summary":"Santen and SERI to advance disease-modifying therapies for major eye diseases in Singapore - BioSpectrum Asia","headline":"Santen and SERI to advance disease-modifying therapies for major eye diseases in Singapore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQZ2pjSjF2NlA1ZnlpWk05bktYZUl3S1dtajFfdVo2dk9RNF9IMUYyOUhCMU1TeVZlbVRqbVhsSmVWajJwR2Y2aGZweXEwZEp5T1hzUzliQTZUczZzOHJKQ3p0ZEo3LWh1d1JFM1JHVjBjQk9Jd1pKdmoySlFtdVoxdHNsRk52LXM5TjdaUTVBaVVfalcyS1JUWUsxN2k3cHB2eDAzcjhxanVYTnJHWVcxVm45NHdtcVpFWmc?oc=5","date":"2025-10-20","type":"deal","source":"Pearce IP","summary":"Santen Pharmaceuticals Inks South Korea Deal with Novartis for Lucentis® and Beovu® - Pearce IP","headline":"Santen Pharmaceuticals Inks South Korea Deal with Novartis for Lucentis® and Beovu®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPeXZQdUJoTkM0SlVFeF9EUnFQM0NFS0VaeHhVRWVKYWg0T1hzblpPam9OLUtuakxfbWhvTTFVSnYzRWFWUTZYeHgtSkRPa1hBdVotaThISU1kTFZmNkFDcm53LVktZjRFLW5xWXllZ0xmX09rRVEzYW9oMVJZNFNfMldDSXVRWUs1ZHRPUXlKOG9yT0ZOa1l5dklaQWxVNjNoWm9NUzZwQzQ2MXhYYUd5SQ?oc=5","date":"2025-08-22","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—J&J's $2B Fujifilm deal; Drug recalls for 3 Indian firms; RemeGen, Santen's eye med pact - Fierce Pharma","headline":"Fierce Pharma Asia—J&J's $2B Fujifilm deal; Drug recalls for 3 Indian firms; RemeGen, Santen's eye med pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQLVJsRjJIeDZOUDNtejNOXzQwRWJ2cnhqY2lneU5aYy1lVFFiWTl6SjJTYkZLOGVhY3piZkpJUXVHa3oyNGdkVVlTdzBwUjFWdGFrdXBpVF9HZFpVUlJ3LWFDQVQ1RkJob3JMdUkwR3c0MDRJeENhTmlVTDdOSmRiY0dnSEtJdDM1dS1Lb0FBRW0zcWRhTlZfWjdYazlzZw?oc=5","date":"2025-08-19","type":"deal","source":"Fierce Biotech","summary":"China's RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal - Fierce Biotech","headline":"China's RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPUkxjdlNfeVVYdUcwSWFyX2N2UUF2ODJuUGVXMXktbFQway0wdGxCcUxKdEhxS1k3YWwtUVRqUTl2RXFXUkZGQ2haejFySzFqTWFBeFpzUHBLUDItUTdBenNsWldIb2JZb20yM01NQ1hoN2o0ZmtrWkFfcjdwUEdzVjJDV0NqWFVKYXo4SGl5MHI3dw?oc=5","date":"2025-08-19","type":"deal","source":"Pharmaceutical Technology","summary":"Santen and RemeGen sign licence deal for retinal disease injection - Pharmaceutical Technology","headline":"Santen and RemeGen sign licence deal for retinal disease injection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNd1gxZ0tUU0dxMkN2bjRNQVptQXBJODBXTEpsRklRMFc5TkVCN0lOUGM3SUh3eEFTakUwZGRJbW1vM2V2aEFoMGFXZFc1b181MWJoY054ckx3WGR6RzhnakhPTkVxeUF1bkZfXzd3YW53NFI5T0xyS2xlcFBvT1FJNXN4UVY4NXVLU1dnRHdGVFNocnVYaW92RkQtVmZjZWxra20yLXl3MFFFZnpWbG5LeDI0TWxNSWQyUjZUTUxqN0FOSER2bF9tQl81b19McE5nSGQ4VzRvc0pNbmttekxGVThZVjhSaEEwMHkyeHliRVZhU19IYXF1clFRdFZja2VfS0FwbHNqUWoycUU4YXBsZjVONmxhRlhhVVE?oc=5","date":"2025-08-18","type":"pipeline","source":"PR Newswire","summary":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries - PR Newswire","headline":"RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYkw0V2NXT2YwTUJzcS0xd25uV1lYQXBQTUVCTXN4VW4zVWwwLVpONTBYLU1PMTZsNVJSaFVYX2w0Qk1KV3J2SzhjVlhOUEwwN2o1Q29PSXlKWXQtY3cxR2xIUy1UUnVHaUdyZDFKNV9UbkhMQ0I0T3BnTVIxYXVRYXBQMEJrSUE4VVNScUpVVUJLSk4ydWR4bWE5LUFmTDhxX3l6OGo1RTQ?oc=5","date":"2025-06-02","type":"pipeline","source":"Bloomberg.com","summary":"Watch TriVista Capital CEO: Long on Santen Pharmaceutical - Bloomberg.com","headline":"Watch TriVista Capital CEO: Long on Santen Pharmaceutical","sentiment":"neutral"}],"patents":[],"drugCount":45,"phaseCounts":{"marketed":8,"phase_3":17,"phase_1":2,"phase_2":18},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}